Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

Abstract

Induction of antigen-specific CD8 + T cells offers the prospect of immunization against many infectious diseases, but no subunit vaccine has induced CD8 + T cells that correlate with efficacy in humans. Here we demonstrate that a replication-deficient chimpanzee adenovirus vector followed by a modified vaccinia virus Ankara booster induces exceptionally high frequency T-cell responses (median >2400 SFC/10 6 peripheral blood mononuclear cells) to the liver-stage Plasmodium falciparum malaria antigen ME-TRAP. It induces sterile protective efficacy against heterologous strain sporozoites in three vaccinees (3/14, 21%), and delays time to patency through substantial reduction of liver-stage parasite burden in five more (5/14, 36%), P =0.008 compared with controls. The frequency of monofunctional interferon-γ-producing CD8 + T cells, but not antibodies, correlates with sterile protection and delay in time to patency ( P corrected =0.005). Vaccine-induced CD8 + T cells provide protection against human malaria, suggesting that a major limitation of previous vaccination approaches has been the insufficient magnitude of induced T cells.

References 48

1. 1.

   Robinson H. L. & Amara R. R. T cell vaccines for microbial infections. Nat. Med. 11, S25–S32 (2005 ).

   Not in our library10.1038/nm1212

2. 2.

   Topham D. J., Tripp R. A. & Doherty P. C. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159, 5197–5200 (1997 ).

   Not in our library

3. 3.

   Gillespie G. M. et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J. Virol. 74, 8140–8150 (2000 ).

   Not in our library10.1128/jvi.74.17.8140-8150.2000

4. 4.

   Callan M. F. The evolution of antigen-specific CD8+ T cell responses after natural primary infection of humans with Epstein-Barr virus. Viral Immunol. 16, 3–16 (2003 ).

   Not in our library10.1089/088282403763635401

5. 5.

   Borrow P., Lewicki H., Hahn B. H., Shaw G. M. & Oldstone M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103–6110 (1994 ).

   Not in our library10.1128/jvi.68.9.6103-6110.1994

6. 6.

   Betts M. R. et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983–11991 (2001 ).

   Not in our library10.1128/jvi.75.24.11983-11991.2001

7. 7.

   Arens R. & Schoenberger S. P. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol. Rev. 235, 190–205 (2010 ).

   Not in our library10.1111/j.0105-2896.2010.00899.x

8. 8.

   Whelan K. T. et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One 4, e5934 (2009 ).

   Not in our library10.1371/journal.pone.0005934

9. 9.

   Darrah P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843–850 (2007 ).

   Not in our library10.1038/nm1592

10. 10.

    Schmidt N. W. et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl Acad. Sci. USA 105, 14017–14022 (2008 ).

    Not in our library10.1073/pnas.0805452105

11. 11.

    Reyes-Sandoval A. et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78, 145–153 (2010 ).

    Not in our library10.1128/iai.00740-09

12. 12.

    Liu J. et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87–91 (2009 ).

    Not in our library10.1038/nature07469

13. 13.

    Doolan D. L. et al. DNA vaccines for malaria: the past, the present, & the future. Ind. J. Med. Res. 106, 109–119 (1997 ).

    Not in our library

14. 14.

    Schneider J. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397–402 (1998 ).

    Not in our library10.1038/nm0498-397

15. 15.

    Li S. et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl Acad. Sci. USA 90, 5214–5218 (1993 ).

    Not in our library10.1073/pnas.90.11.5214

16. 16.

    Gilbert S. C. et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20, 1039–1045 (2002 ).

    Not in our library10.1016/s0264-410x(01)00450-9

17. 17.

    McConkey S. J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729–735 (2003 ).

    Not in our library10.1038/nm881

18. 18.

    Webster D. P. et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102, 4836–4841 (2005 ).

    Not in our library10.1073/pnas.0406381102

19. 19.

    Colloca S. et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4, (2012 ).

    Not in our library10.1126/scitranslmed.3002925

20. 20.

    RTS,S Clinical Trials Partnership. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. N. Engl. J. Med. 367, 2284–2295 (2012 ).

    Not in our library10.1056/nejmoa1208394

21. 21.

    Agnandji S. T. et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863–1875 (2011 ).

    Not in our library10.1056/nejmoa1102287

22. 22.

    Hutchings C. L., Birkett A. J., Moore A. C. & Hill A. V. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect. Immun. 75, 5819–5826 (2007 ).

    Not in our library10.1128/iai.00828-07

23. 23.

    O’Hara G. A. et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205, 772–781 (2012 ).

    Not in our library10.1093/infdis/jir850

24. 24.

    Capone S. et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29, 256–265 (2010 ).

    Not in our library10.1016/j.vaccine.2010.10.041

25. 25.

    Buchbinder S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008 ).

    Not in our library10.1016/s0140-6736(08)61591-3

26. 26.

    Dangoor A. et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol. Immunother 59, 863–873 (2010 ).

    Not in our library10.1007/s00262-009-0811-7

27. 27.

    Tamminga C. et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6, e25868 (2011 ).

    Not in our library10.1371/journal.pone.0025868

28. 28.

    Dunachie S. J. et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74, 5933–5942 (2006 ).

    Not in our library10.1128/iai.00590-06

29. 29.

    Bejon P. et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191, 619–626 (2005 ).

    Not in our library10.1086/427243

30. 30.

    Andrews L. et al. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am. J. Trop. Med. Hyg. 73, 191–198 (2005 ).

    Not in our library

31. 31.

    Wang R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476–480 (1998 ).

    Not in our library10.1126/science.282.5388.476

32. 32.

    Epstein J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334, 475–480 (2011 ).

    Not in our library10.1126/science.1211548

33. 33.

    Bett A. J. et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 28, 7881–7889 (2010 ).

    Not in our library10.1016/j.vaccine.2010.09.079

34. 34.

    Dudareva M. et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27, 3501–3504 (2009 ).

    Not in our library10.1016/j.vaccine.2009.03.080

35. 35.

    Chen H. et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J. Virol. 84, 10522–10532 (2010 ).

    Not in our library10.1128/jvi.00450-10

36. 36.

    Kester K. E. et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26, 2191–2202 (2008 ).

    Not in our library10.1016/j.vaccine.2008.02.048

37. 37.

    Kester K. E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337–346 (2009 ).

    Not in our library10.1086/600120

38. 38.

    Barouch D. H. et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J. Virol. 83, 9584–9590 (2009 ).

    Not in our library10.1128/jvi.00821-09

39. 39.
    Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors · 2012

    No notice
40. 40.

    Sheehy S. H. et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 19, 2269–2276 (2011 ).

    Not in our library10.1038/mt.2011.176

Cited by papers we hold 7

• Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria · 2022
  Not checked
• Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors · 2018
  Not checked
• Malaria Vaccines: Recent Advances and New Horizons · 2018
  No notice
• Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine · 2017
  No notice
• A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys · 2015
  No notice
• Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals · 2014
  No notice
• Vaccines against malaria · 2011
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.